Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John J Powers

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Cancer Treatment and Research Communications|December 21, 2020
Exposure to a mycovirus containing Aspergillus Flavus reproduces acute lymphoblastic leukemia cell surface and genetic markers in cells from patients in remission and not controlsCameron K Tebbi, Aruna Badiga, Eva Sahakian, et al.
Current Pharmaceutical Design|January 30, 2010
Circumventing immune tolerance through epigenetic modificationJason A Dubovsky, Alejandro Villagra, John J Powers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2009
Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigenJason A Dubovsky, Douglas G McNeel, John J Powers, et al.
Leukemia Research|March 8, 2011
Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidineJason A Dubovsky, John J Powers, Yang Gao, et al.
Frontiers in Immunology|December 17, 2020
HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 ModelKamira Maharaj, John J Powers, Melanie Mediavilla-Varela, et al.
Leukemia Research|September 25, 2010
Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiersJason A Dubovsky, Daniel Wang, John J Powers, et al.
Leukemia & Lymphoma|January 29, 2011
A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitorsJohn J Powers, Jason A Dubovsky, P K Epling-Burnette, et al.
Frontiers in Oncology|December 19, 2022
Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanomaAhmad A Tarhini, Wissam B Hanayneh, John J Powers, et al.
Journal of Pediatric Hematology/Oncology|June 25, 2020
Plasma of Acute Lymphoblastic Leukemia Patients React to the Culture of a Mycovirus Containing Aspergillus flavusCameron K Tebbi, Aruna Badiga, Eva Sahakian, et al.
Biorxiv : the Preprint Server for Biology|April 24, 2026
Adaptive Responses Directed by CREB Control Epithelial-Mesenchymal Plasticity in CancerKshitij Parag-Sharma, Harish Bharambe, John J Powers, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Cancer Treatment and Research Communications|December 21, 2020
Exposure to a mycovirus containing Aspergillus Flavus reproduces acute lymphoblastic leukemia cell surface and genetic markers in cells from patients in remission and not controlsCameron K Tebbi, Aruna Badiga, Eva Sahakian, et al.
Current Pharmaceutical Design|January 30, 2010
Circumventing immune tolerance through epigenetic modificationJason A Dubovsky, Alejandro Villagra, John J Powers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2009
Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigenJason A Dubovsky, Douglas G McNeel, John J Powers, et al.
Leukemia Research|March 8, 2011
Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidineJason A Dubovsky, John J Powers, Yang Gao, et al.
Frontiers in Immunology|December 17, 2020
HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 ModelKamira Maharaj, John J Powers, Melanie Mediavilla-Varela, et al.
Leukemia Research|September 25, 2010
Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiersJason A Dubovsky, Daniel Wang, John J Powers, et al.
Leukemia & Lymphoma|January 29, 2011
A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitorsJohn J Powers, Jason A Dubovsky, P K Epling-Burnette, et al.
Frontiers in Oncology|December 19, 2022
Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanomaAhmad A Tarhini, Wissam B Hanayneh, John J Powers, et al.
Journal of Pediatric Hematology/Oncology|June 25, 2020
Plasma of Acute Lymphoblastic Leukemia Patients React to the Culture of a Mycovirus Containing Aspergillus flavusCameron K Tebbi, Aruna Badiga, Eva Sahakian, et al.
Biorxiv : the Preprint Server for Biology|April 24, 2026
Adaptive Responses Directed by CREB Control Epithelial-Mesenchymal Plasticity in CancerKshitij Parag-Sharma, Harish Bharambe, John J Powers, et al.
Pageof 3